Merck announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet

05-03-2014 Business Wire HealthComments (0)

Merck & CoPharmaceuticalUSA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego. The study was conducted in 124 adult patients 18 y

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top